专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10660962B2 Silicone-based composition for skin treatment 有权
公开(公告)号：US10660962B2
公开(公告)日：2020-05-26
申请号：US16121184
申请日：2018-09-04
申请人： CMPD Licensing, LLC
发明人： Jay Richard Ray, II , Charles D. Hodge
IPC分类号： A61K47/34 , A61K9/00 , A61K47/24 , A61K9/06 , A61K31/67 , A61K31/195 , A61K31/4545 , A61K31/695 , A61K31/56 , A61K45/06 , A61K47/22 , A61K47/10 , A61K31/167
摘要： The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine. The silicone-based gel may include additional active ingredients, such as NSAIDs, anticonvulsants, antidepressants, muscle relaxants, and/or other active ingredients.

2. 发明申请

US20170182167A1 SILICONE-BASED COMPOSITION FOR SKIN TREATMENT 审中-公开
公开(公告)号：US20170182167A1
公开(公告)日：2017-06-29
申请号：US15457003
申请日：2017-03-13
申请人： CMPD Licensing, LLC
发明人： Jay Richard Ray, II , Charles D. Hodge
IPC分类号： A61K47/34 , A61K9/06 , A61K31/56 , A61K45/06 , A61K31/195 , A61K31/167 , A61K47/22 , A61K47/10 , A61K9/00 , A61K31/4545
CPC分类号： A61K47/34 , A61K9/0014 , A61K9/06 , A61K31/167 , A61K31/195 , A61K31/4545 , A61K31/56 , A61K31/695 , A61K45/06 , A61K47/10 , A61K47/22 , A61K47/24 , A61K2300/00
摘要： The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine. The silicone-based gel may include additional active ingredients, such as NSAIDs, anticonvulsants, antidepressants, muscle relaxants, and/or other active ingredients.

3. 发明申请

US20150182538A1 SILICONE-BASED COMPOSITION FOR SKIN TREATMENT 审中-公开
标题翻译：基于硅胶的皮肤治疗组合物
公开(公告)号：US20150182538A1
公开(公告)日：2015-07-02
申请号：US14643704
申请日：2015-03-10
申请人： CMPD LICENSING, LLC
发明人： Jay Richard Ray, II , Charles D. Hodge
IPC分类号： A61K31/56 , A61K31/4545 , A61K31/195 , A61K47/24 , A61K9/00 , A61K45/06 , A61K9/06 , A61K47/34 , A61K31/167
CPC分类号： A61K47/34 , A61K9/0014 , A61K9/06 , A61K31/167 , A61K31/195 , A61K31/4545 , A61K31/56 , A61K31/695 , A61K45/06 , A61K47/10 , A61K47/22 , A61K47/24 , A61K2300/00
摘要： The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine. The silicone-based gel may include additional active ingredients, such as NSAIDs, anticonvulsants, antidepressants, muscle relaxants, and/or other active ingredients.
摘要翻译：本实施方案可涉及用于治疗瘢痕组织，皮肤病症和/或其它疾病的局部递送的复合药物。一方面，透皮霜或凝胶可以同时提供多种药物的有效施用。优选地，可以提供基于硅氧烷的凝胶作为基础组合物，并且可以具有非零百分比的硅氧烷或硅氧烷变体。硅氧烷基凝胶可以包括环戊硅氧烷，聚硅氧烷-11，聚二甲基硅氧烷和C30-45烷基鲸蜡硬脂基聚二甲基硅氧烷交联聚合物，并且包括几种活性成分，例如糖皮质激素，抗组胺剂和神经抑制剂。硅氧烷基凝胶可以包括氟替卡松，氯雷他定和加巴喷丁的组合。氟替卡松和氯雷他定的浓度可能相对较低，而加巴喷丁的浓度中等程度较高。硅氧烷基凝胶还可以具有一种或多种局部麻醉剂，如丙卡因和/或利多卡因。硅氧烷基凝胶可以包括另外的活性成分，例如NSAID，抗惊厥药，抗抑郁药，肌肉松弛剂和/或其它活性成分。

4. 发明申请

US20190060464A1 SILICONE-BASED COMPOSITION FOR SKIN TREATMENT 审中-公开
公开(公告)号：US20190060464A1
公开(公告)日：2019-02-28
申请号：US16121184
申请日：2018-09-04
申请人： CMPD Licensing, LLC
发明人： Jay Richard Ray, II , Charles D. Hodge
IPC分类号： A61K47/34 , A61K45/06 , A61K31/56 , A61K47/24 , A61K9/00 , A61K9/06 , A61K47/10 , A61K47/22 , A61K31/167 , A61K31/195 , A61K31/4545 , A61K31/695
CPC分类号： A61K47/34 , A61K9/0014 , A61K9/06 , A61K31/167 , A61K31/195 , A61K31/4545 , A61K31/56 , A61K31/695 , A61K45/06 , A61K47/10 , A61K47/22 , A61K47/24 , A61K2300/00
摘要： The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine. The silicone-based gel may include additional active ingredients, such as NSAIDs, anticonvulsants, antidepressants, muscle relaxants, and/or other active ingredients.

5. 发明授权

US10064949B2 Silicone-based composition for skin treatment 有权
公开(公告)号：US10064949B2
公开(公告)日：2018-09-04
申请号：US15457003
申请日：2017-03-13
申请人： CMPD Licensing, LLC
发明人： Jay Richard Ray, II , Charles D. Hodge
IPC分类号： A61K9/00 , A61K9/06 , A61K31/56 , A61K31/67 , A61K31/195 , A61K31/4545 , A61K45/06 , A61K47/10 , A61K47/22 , A61K47/34 , A61K31/167
摘要： The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine. The silicone-based gel may include additional active ingredients, such as NSAIDs, anticonvulsants, antidepressants, muscle relaxants, and/or other active ingredients.

6. 发明授权

US09271989B2 Silicone-based composition for skin treatment 有权
标题翻译：用于皮肤治疗的基于硅酮的组合物
公开(公告)号：US09271989B2
公开(公告)日：2016-03-01
申请号：US14643704
申请日：2015-03-10
申请人： CMPD LICENSING, LLC
发明人： Jay Richard Ray, II , Charles D. Hodge
IPC分类号： A61K31/167 , A61K31/195 , A61K31/4545 , A61K31/56 , A61K31/695 , A61K47/24 , A61K47/34 , A61K9/00 , A61K9/06 , A61K45/06
CPC分类号： A61K47/34 , A61K9/0014 , A61K9/06 , A61K31/167 , A61K31/195 , A61K31/4545 , A61K31/56 , A61K31/695 , A61K45/06 , A61K47/10 , A61K47/22 , A61K47/24 , A61K2300/00
摘要： The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine. The silicone-based gel may include additional active ingredients, such as NSAIDs, anticonvulsants, antidepressants, muscle relaxants, and/or other active ingredients.
摘要翻译：本实施方案可涉及用于治疗瘢痕组织，皮肤病症和/或其它疾病的局部递送的复合药物。一方面，透皮霜或凝胶可以同时提供多种药物的有效施用。优选地，可以提供基于硅氧烷的凝胶作为基础组合物，并且可以具有非零百分比的硅氧烷或硅氧烷变体。硅氧烷基凝胶可以包括环戊硅氧烷，聚硅氧烷-11，聚二甲基硅氧烷和C30-45烷基鲸蜡硬脂基聚二甲基硅氧烷交联聚合物，并且包括几种活性成分，例如糖皮质激素，抗组胺剂和神经抑制剂。硅氧烷基凝胶可以包括氟替卡松，氯雷他定和加巴喷丁的组合。氟替卡松和氯雷他定的浓度可能相对较低，而加巴喷丁的浓度中等程度较高。硅氧烷基凝胶还可以具有一种或多种局部麻醉剂，如丙卡因和/或利多卡因。硅氧烷基凝胶可以包括另外的活性成分，例如NSAID，抗惊厥药，抗抑郁药，肌肉松弛剂和/或其它活性成分。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式